摘要
目的:探讨非小细胞肺癌(NSCLC)患者采用复阳化积方联合替雷利珠单抗治疗的临床效果。方法:选取2022年3月—2023年12月洪湖市中医医院收治的80例NSCLC患者,以随机数表法分成研究组(n=40)与对照组(n=40),对照组采用替雷利珠单抗治疗,研究组采用复阳化积方联合替雷利珠单抗治疗。比较两组临床疗效、中医症候积分、肿瘤标志物[鳞状细胞癌抗原(SCC)、糖类抗原199(CA199)、糖类抗原125(CA125)]、细胞免疫功能[T淋巴细胞亚群(CD3^(+)、CD4^(+)、CD8^(+))]、不良反应发生率。结果:研究组客观缓解率(ORR)、疾病控制率(DCR)较对照组更高,差异有统计学意义(P<0.05);两组治疗后中医症候积分下降,研究组较对照组更低,差异有统计学意义(P<0.05);两组治疗后SCC、CA199、CA125水平下降,研究组较对照组更低,差异有统计学意义(P<0.05);两组治疗后CD3^(+)、CD4^(+)升高,CD8下降,研究组CD3^(+)、CD4^(+)较对照组更高,CD8更低,差异有统计学意义(P<0.05);研究组不良反应发生率为15.00%(6/40),较对照组的40.00%(16/40)更低,差异有统计学意义(P<0.05)。结论:复阳化积方联合替雷利珠单抗应用于NSCLC患者治疗中,能够提高临床疗效,降低中医症候积分及肿瘤标志物水平,改善细胞免疫功能,减少不良反应发生。
Objective:To explore the clinical efficacy of the combination of Fuyang Huaji Formula and Tislelizumab in the treatment of non-small cell lung cancer(NSCLC).Method:Eighty patients with NSCLC treated in Honghu Traditional Chinese Medicine Hospital from March 2022 to December 2023 were selected and divided into study group(n=40)and control group(n=40)by random number table method.The control group was treated with Tislelizumab,and the study group was treated with Fuyang Huaji Formula combined with Tislelizumab.The clinical efficacy,traditional Chinese medicine symptom score,tumor markers[squamous cell carcinoma antigen(SCC),carbohydrate antigen 199(CA199),carbohydrate antigen 125(CA125)],cellular immune function[T lymphocyte subsets(CD3^(+),CD4^(+),CD8^(+))]and incidence of adverse reactions were compared between the two groups.Result:The objective response rate(ORR)and disease control rate(DCR)of the study group were higher than those of the control group,and the differences were statistically significant(P<0.05).The scores of traditional Chinese medicine symptoms of the two groups decreased after treatment,and the study group was lower than the control group,the differences were statistically significant(P<0.05).After treatment,the levels of SCC,CA199 and CA125 decreased in the two groups,and the levels in the study group were lower than those in the control group,the differences were statistically significant(P<0.05).After treatment,CD3^(+) and CD4^(+) increased and CD8 decreased in the two groups,the CD3^(+) and CD4^(+) in the study group were higher than those in the control group,and CD8 was lower,the differences were statistically significant(P<0.05).The incidence of adverse reactions in the study group was 15.00%(6/40),which was lower than 40.00%(16/40)in the control group,and the difference was statistically significant(P<0.05).Conclusion:The combination of Fuyang Huaji Formula and Tislelizumab in the treatment of NSCLC patients can improve clinical efficacy,reduce traditional Chinese medicine syndrome scores and tumor marker levels,improve cellular immune function,and reduce the occurrence of adverse reactions.
作者
江小霞
舒兴卫
叶勇
JIANG Xiaoxia;SHU Xingwei;YE Yong(Honghu Traditional Chinese Medicine Hospital,Honghu 433200,China;不详)
出处
《中外医学研究》
2025年第13期1-5,共5页
CHINESE AND FOREIGN MEDICAL RESEARCH
基金
湖北省中医药管理局中医药科研项目(ZY2023M052)。
